News and Announcements
Pelikin secure 20% of funding target within the first 4 weeks from a single investor
- Published October 16, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Pelikin kicked off the funding round (A$2m) with a bang securing 20% of the funding target within the first 4 weeks from a single investor. This has allowed Pelikin to speed up product development and make moves on the marketing campaigns.
Here are some more Pelikin highlights from the past couple of months:
- Featured in Escape.com.au, Anthill Magazine, Chattr, Australian Fintech, Hipland.co.
- Opened A$2m capital raise in June – secured $400k in July.
- Soft launched the app for both iPhone and Android users. To activate use a code SQUAD19
- Card usage hit over 35 countries!
- Launched a game changing money tool for group travellers.
- David Monty (Founder/CEO Tuxedo Money) added to Pelikin Advisory Board.
- Signed deal with insurtech Travel By Us to build Pelikin Travel Insurance backed by Lloyds
- Kicked off conversations with some exciting strategic partners to broaden the value proposition.
About Pelikin
Pelikin is a multi-currency free banking app and pre-paid Visa card for young travellers. It helps millennials spend, send and manage their cash money overseas, without bank fees or annoying red tape. After nailing down partnerships with Heritage Bank (ADI) and Visa, and following a successful global product beta, the Melbourne fintech is set to launch in Q4 2019.
Pelikin is currently raising A$2 million to boost customer acquisition and product development, with an eye on the NZ and US markets.
To keep up to date with Pelikin, register your interest in the company below.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
